Jose A. Climent-Martinez

Pamplona, NC 31008, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas.

Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas.

Journal: Cancers

Published: March 05, 2026

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

Journal: Blood

Published: March 02, 2026

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

Journal: Blood

Published: February 25, 2026

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Journal: bioRxiv : the preprint server for biology

Published: December 19, 2025

Decoding the Heterogeneity of Diffuse Large B-Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B-Cell Lymphoma Cell Lines.

Decoding the Heterogeneity of Diffuse Large B-Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B-Cell Lymphoma Cell Lines.

Journal: Hematological oncology

Published: December 10, 2025

NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.

NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.

Journal: Blood

Published: October 10, 2025

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Journal: Molecular cancer

Published: September 08, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood

Published: July 21, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood

Published: July 21, 2025

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Journal: Nature communications

Published: July 12, 2025

Editorial special issue: Frontiers in cancer, obesity and metabolism.

Editorial special issue: Frontiers in cancer, obesity and metabolism.

Journal: Journal of physiology and biochemistry

Published: June 19, 2025

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Journal: Blood

Published: April 14, 2025

Showing 1-12 of 72

Last Updated: 09/26/2026